MICRO-X LIMITED (ASX: MX1)
Health care · News and insights
Price unavailable
Latest MX1 announcements
Announcement Insights
Micro-X Rover Orders Rebound as Medical CT Remains Strategic Focus
Micro-X reported a recovery in Rover demand, with 10 orders in the September quarter and seven more after quarter-end; quarterly product sales receipts rose to $1.20 million from $0.20 million in the June quarter. The company also reported a threefold expansion in its Rover sales pipeline and more than $3 million in annualised cost savings, while maintaining its strategic focus on medical CT. Separately, Acorn Capital’s voting power fell to 8.72% from 9.74% after share sales between July and November.
Updated 12 Nov 2026, 04:06 PM Sydney time
Sources
Change in substantial holdingMX1 - 2026 AGM Results of MeetingMX1 - Quarterly Results PresentationMX1 - Quarterly Activities Report & Appendix 4CComments
2026-11-12 · Health care
MX1: $0.030 +0.00% · MC: $23M
Acorn Capital Limited’s voting power in Micro-X fell to 8.72% from 9.74%, after a series of share sales between July and November. At Micro-X’s AGM, shareholders also approved the 10% placement facility, with 76.34% of votes cast in favour.
Updated 2026-11-12 15:53
Sources
Change in substantial holdingMX1 - 2026 AGM Results of MeetingComments
2026-11-04 · Health care
MX1: $0.032 +0.00% · MC: $23M
Micro-X’s results presentation reiterates its strategic focus on medical CT and reports ten Rover orders during the September quarter, followed by seven more after quarter-end. The earlier quarterly update said quarterly product sales receipts rose from $0.2 million to $1.2 million, while the company also reported a threefold expansion in its Rover sales pipeline.
Updated 2026-11-04 09:55
Sources
MX1 - Quarterly Results PresentationComments
2026-10-30 · Health care
MX1: $0.036 -7.69% · MC: $23M
Micro-X received orders for 10 Rover units during the quarter, followed by orders for seven more after quarter-end; quarterly product sales receipts rose from the June quarter. The company says its Rover sales pipeline grew threefold during the quarter, while it implemented more than $3 million in annualised cost savings and reported $4.4 million of operating cash outflow, including one-off restructuring and ARPA-H pass-through costs. Shareholders approved $8 million in convertible note financing, of which $6 million was settled during the quarter, to support the company’s strategic focus on medical CT.
Updated 2026-10-30 12:30
Sources
MX1 - Quarterly Activities Report & Appendix 4CComments
Comments